30 Days Results of Boston Scientific's Lotus TAVR Valve Presented at TCT

At the recent Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco, Boston Scientific's entry into the transaortic valve replacement (TAVR) field was highlighted in a First Report Investigation report of the REPRISE II Trial, studying the Lotus Valve. Dr. Ian Meredith of the Monash Medical Centre in Melbourne, Australia, presented the 30-day results of 120 patients who received this unique repositionable valve.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news